Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Free Report) – HC Wainwright issued their FY2026 earnings estimates for Basilea Pharmaceutica in a report released on Monday, September 22nd. HC Wainwright analyst R. Selvaraju expects that the company will earn $4.93 per share for the year.
Basilea Pharmaceutica Stock Performance
Shares of OTCMKTS:BPMUF opened at $67.75 on Thursday. The stock’s 50-day moving average is $66.72 and its 200 day moving average is $57.80. The company has a debt-to-equity ratio of 1.18, a quick ratio of 4.16 and a current ratio of 4.85. Basilea Pharmaceutica has a 1 year low of $47.50 and a 1 year high of $67.75.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Recommended Stories
- Five stocks we like better than Basilea Pharmaceutica
- The Most Important Warren Buffett Stock for Investors: His Own
- Lower Rates Put RV Stocks Back in the Fast Lane
- Why Are Stock Sectors Important to Successful Investing?
- Alphabet: Time to Take Profits, Buy, or Wait for a Pullback?
- What Investors Need to Know About Upcoming IPOs
- Hershey vs. Mondelez: Which Stock Wins Chocolate Season?
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
